Medication

Photo

Novartis launched once-a-year osteoporosis treatment

The Swiss company Novartis recently received the FDA approval for the U.S. market for their new osteoporosis drug “Reclast”, a therapy that is only given once a year via a 15-minute infusion. The new treatment option is especially designed for women who suffer from post-menopausal osteoporosis.

Photo

Contrast Harmonic Imaging (CHI)

Case 1 50-year-old male with a colorectal cancer. Greyscale imaging clearly shows the lesion, as an echogenic 3 cm mass (Fig.l a), which must be considered as suspicious for a metastasis from his colorectal cancer but benefit of the doubt must be given. Colour Doppler (Fig. 1b) is not helpful. At 33 seconds after SonoVue injection (early sinusoidal phase), Vascular Recognition Imaging (VRI)…

Photo

Article • Ophthalmology

Aetiology of glaucoma

A study of european scientists reveals that misfolded amyloid beta proteins, generally regarded as the cause for Alzheimer's disease, could also cause glaucoma. The scientists tested several drugs and their effect on the progression of glaucoma - pharmaceuticals usually used to treat Alzheimer's disease had most effect.

Photo

Treating Alzheimer with a skin patch

“Exelon Patch”, developed by Novartis is the first skin patch to treat patients with mild to moderate Alzheimer disease. The new therapy that has already been approved by the FDA, is said to be more compliant for it causes less incidents of nausea and vomiting.

Photo

Breakthrough in lymphatic cancer treatment

Celebrating his 71st birthday this year, Czech chemist Professor Antonin Holy will also be able to celebrate the launch of clinical testing of a drug to treat non-Hodgkins Lymphoma (NHL) and chronic lymphatic leukaemia (CLL) - adding another to his 60+ registered patents.

Photo

Virtual TB bacillus should help finding new drugs

Today little is known about the metabolism of the tuberculosis bacillus and, because of its slow growth, experiments for new drugs take a long time. Now a team of researchers form the University of Surrey built an in silico model of the agent that causes TB - a virtual TB bacillus - that promises to speed up the drug discovery process.

Photo

European Parliament opens door for advanced therapies

The European Parliament voted for an EU Regulation on advanced therapies like gene therapy, cell therapy and tissue engineering. The decision, if adopted by the council, could open the door for innovative therapies which have a huge potential for curing diseases such as Parkionson´s, Alzheimer or cancer.

Photo

Bless you! The allergy season has begun

The beautiful weather not only causes high spirit but also seasonal allergies. And as every year, over-the-counter allergy medications are booming, whereas most of the patients are extremely thoughtless concerning the use of antihistamines, not being aware of the side effects.

Photo

Bitter pill for pharmacists

Many French pharmacists are falling on hard times after a year of falling revenues. Those most affected are in rural or semi-rural areas, where there is a growing shortage of doctors willing to set up practice or where resident GPs are leaving for the more populous towns.

Photo

Company Round-up

Siemens Medical Solutions strengthens its diagnostics devision, J&J wins stent patent appeal over Boston Scientific and Medtronic, Leica extends its product range and GE Healthcare cooperates with Ludwig-Maximilian-Universität in Munich as a reference center and strategic partner in developing cell-based assay modes.

Photo

Antibiotics for Africa and Latin America

A donation of the antibiotic Cipro® (Bayer HealthCare) with a wholesale value of more than US$ 25 million has been given to the non-profit organization MAP (Medical Assistance Programs) who will distribute it to clinics and hospitals in Africa and Latin America, which suffer badly from the lack of essential drugs.

38 show more articles
Subscribe to Newsletter